Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
BSX rallies 40.5% in a year, fueled by WATCHMAN growth, MedSurg gains, acquisitions and global expansion efforts.
MARLBOROUGH, Mass. , July 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2025, on Wednesday, July 23, 2025, at 8:00 a.m.
22 Jul 2025 (In 2 weeks) Date | | 0.72 Cons. EPS | - EPS |
22 Apr 2025 Date | | - Cons. EPS | - EPS |
29 Jan 2025 Date | | 0.66 Cons. EPS | 0.7 EPS |
24 Oct 2024 Date | | 0.59 Cons. EPS | - EPS |
23 Oct 2024 Date | | 0.59 Cons. EPS | 0.63 EPS |
22 Jul 2025 (In 2 weeks) Date | | 0.72 Cons. EPS | - EPS |
22 Apr 2025 Date | | - Cons. EPS | - EPS |
29 Jan 2025 Date | | 0.66 Cons. EPS | 0.7 EPS |
24 Oct 2024 Date | | 0.59 Cons. EPS | - EPS |
23 Oct 2024 Date | | 0.59 Cons. EPS | 0.63 EPS |
Medical - Devices Industry | Healthcare Sector | Michael F. Mahoney CEO | XMEX Exchange | US1011371077 ISIN |
US Country | 53,000 Employees | - Last Dividend | 6 Nov 2003 Last Split | 18 May 1992 IPO Date |
Boston Scientific Corporation is a global developer, manufacturer, and marketer of medical devices used in a variety of interventional medical specialties. Having begun its operations in 1979, the company has grown to serve a diverse range of medical needs through its two primary segments: MedSurg and Cardiovascular. With its headquarters in Marlborough, Massachusetts, Boston Scientific is committed to improving patient health by providing cutting-edge solutions that address complex medical conditions and enhance the quality of life for patients worldwide.